Functional genomics and cancer drug target discovery.
The recent development of technologies for whole-genome sequencing, copy number analysis and expression profiling enables the generation of comprehensive descriptions of cancer genomes. However, although the structural analysis and expression profiling of tumors and cancer cell lines can allow the identification of candidate molecules that are altered in the malignant state, functional analyses are necessary to confirm such genes as oncogenes or tumor suppressors. Moreover, recent research suggests that tumor cells also depend on synthetic lethal targets, which are not mutated or amplified in cancer genomes; functional genomics screening can facilitate the discovery of such targets. This review provides an overview of the tools available for the study of functional genomics, and discusses recent research involving the use of these tools to identify potential novel drug targets in cancer.
Dana-Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA.
Susan E
SE
Moody
Jesse S
JS
Boehm
David A
DA
Barbie
William C
WC
Hahn
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002874:Chromosome Mapping; D055808:Drug Discovery; D016678:Genome; D023281:Genomics / Q000379:methods* / Q000639:trends*; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D009423:Nervous System Neoplasms / Q000235:genetics; D009857:Oncogenes
D000970:Antineoplastic Agents